Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Non Operating Income (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Non Operating Income for 4 consecutive years, with $97000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 99.07% to $97000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.2 million, a 69.5% decrease, with the full-year FY2024 number at $13.4 million, up 3588.51% from a year prior.
  • Non Operating Income was $97000.0 for Q3 2025 at Century Therapeutics, up from -$2.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $10.4 million in Q3 2024 to a low of -$2.4 million in Q2 2023.
  • A 4-year average of $1.1 million and a median of $12000.0 in 2023 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: tumbled 48200.0% in 2023, then soared 86358.33% in 2024.
  • Century Therapeutics' Non Operating Income stood at $3.0 million in 2022, then tumbled by 100.5% to -$15000.0 in 2023, then soared by 20013.33% to $3.0 million in 2024, then plummeted by 96.75% to $97000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Non Operating Income are $97000.0 (Q3 2025), -$2.3 million (Q2 2025), and $2.4 million (Q1 2025).